Download our whitepaper,
Glaucoma Clinical Trials: Advancing
Intraocular Pressure Management
and Neuroprotection
What's Inside:
- Understanding glaucoma types: open-angle, angle-closure, and normal-tension glaucoma.
- Primary endpoints: intraocular pressure (IOP) reduction and visual field preservation.
- Novel drug delivery systems and sustained-release formulations.
- Neuroprotective agents and emerging treatment modalities.
- Standardized visual field testing and OCT imaging protocols.
- Long-term safety monitoring and patient adherence strategies.
Access your complimentary whitepaper today:
Glaucoma Clinical Research
Glaucoma is a progressive optic neuropathy characterized by irreversible damage to the optic nerve, often associated with elevated intraocular pressure (IOP). Clinical trials in glaucoma focus on evaluating treatments that reduce IOP, preserve visual function, and potentially protect or regenerate retinal ganglion cells.
The field has seen significant innovation in drug delivery systems, including sustained-release implants and novel formulations that improve patient compliance. Additionally, neuroprotective strategies are being explored to address the underlying neurodegeneration in glaucoma beyond IOP control.
iNGENū CRO has deep expertise in glaucoma trial design and execution. We partner with specialized ophthalmology sites that utilize advanced diagnostic equipment, including perimetry, OCT, and tonometry, ensuring precise and consistent data collection throughout the trial lifecycle.
Glaucoma affects over
70 million
people worldwide, with increasing prevalence
IOP reduction of
20-30%
is typically targeted in glaucoma trials
Medication adherence rates average
50-60%
highlighting need for improved delivery systems
Our clinical team has over
120 years
of combined clinical trial experience